Hemagen Diagnostics (Hemagen Diagnostics) EV-to-EBIT : 0.00 (As of Jun. 09, 2024)

Hemagen Diagnostics EV-to-EBIT Chart

Hemagen Diagnostics Annual Data
	Trend	Sep03	Sep04	Sep05	Sep06	Sep07	Sep08	Sep09	Sep10	Sep11	Sep12
EV-to-EBIT		Get a 7-Day Free Trial					53.89	-15.88	22.14	-10.58	-12.57

Hemagen Diagnostics Quarterly Data
	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12
EV-to-EBIT	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Hemagen Diagnostics's EV-to-EBIT

For the Biotechnology subindustry, Hemagen Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemagen Diagnostics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's EV-to-EBIT falls into.

Hemagen Diagnostics EV-to-EBIT Calculation

Hemagen Diagnostics's EV-to-EBIT for today is calculated as:

Hemagen Diagnostics's current Enterprise Value is $0.00 Mil.
Hemagen Diagnostics's EBIT for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemagen Diagnostics  (OTCPK:HMGN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Hemagen Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2012 is calculated as:

Hemagen Diagnostics's Enterprise Value for the quarter that ended in Sep. 2012 was $5.51 Mil.
Hemagen Diagnostics's EBIT for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemagen Diagnostics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Hemagen Diagnostics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemagen Diagnostics (Hemagen Diagnostics) Business Description